CHAMPIONS ONCOLOGY, INC.CSBR

CHAMPIONS ONCOLOGY, INC. Revenue Disclosure

10-KFiled Jul 23, 20251 min read
Revenue from Contracts with Customers
Oncology Revenue

The following table represents disaggregated revenue for the twelve months ended April 30, 2025 and 2024:
Year Ended April 30,
 20252024
Pharmacology services$48,585 $47,035 
TOS data license revenue 4,676 — 
Other TOS revenue3,683 3,102 
Personalized oncology services— 18 
Total oncology revenue$56,944 $50,155 
Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services, and SaaS provided via our Lumin Bioinformatics software.

Contract Balances
Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period. Refer to Note 3 for related balances.

Historical Timeline

Fiscal YearFiled
2025Jul 23, 2025Showing above
2024Jul 19, 2024
2023Jul 24, 2023
2022Jul 22, 2022
2021Jul 26, 2021
2020Jul 28, 2020
2019Jul 29, 2019

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per SharePP&ELeasesSegmentsCommitmentsStock CompensationNew StandardsPay vs Performance